At the Lid Line: Unmasking Demodex Across the OSD Spectrum

Overview
Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs such as collarettes, along with a clearer understanding of the limitations of traditional therapies and the role of newer evidence-based options like lotilaner. Enhancing diagnostic accuracy, individualized treatment selection, and structured follow-up can improve adherence and long-term outcomes. Education focused on these strategies aims to reduce misclassification, optimize care, and improve quality of life for patients with DB.
*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Global Learning Collaborative (GLC) that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. GLC has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.

The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.

Faculty:
Douglas K. Devries, OD
Managing Partner
Eye Care Associates of Nevada
Sparks, NV

Consulting Fees: Aescult, Akorn, Alcon Vision, Allergan, Aldeyra, Avelino, Azura, Bausch & Lomb, BlephEx, Bruder, EyeVance, Johnson & Johnson Vision, Kala, Lumenis, Novaliq, Novartis Pharmaceuticals Corporation, OcuSoft, Ophthalmic Resources, Oyster Point, Quidel, RPS, ScienceBased Health, Sight Sciences, Sun Pharmaceutical, Tarsus, TearLab, Théa, Visus

Cecelia Koetting, OD, FAAO
Assistant Professor
Department of Ophthalmology
University of Colorado School of Medicine
Aurora, CO

Consulting Fees: Alcon Vision, Aldeyra, Allergan/AbbVie, Azura, Bausch & Lomb, Blinkjoy, Brill, Bruder, Dompé, Harrow, Iveric Bio, Kala, MOVU, Myze, Nordic Pharma, NuLids, Orasis, PRN/EyePromise, ScienceBased Health, SCOPE, Sight Sciences, Tarsus, Tenpoint, Topcon, Trukera, Twenty/Twenty, Vital Tears

Reviewers/Content Planners/Authors:
- Tim Person has no relevant relationships to disclose.
- Wilma Guerra has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Distinguish mild Demodex blepharitis from other forms of anterior and posterior blepharitis based on clinical signs and symptoms
- Contrast the efficacy and safety of newly approved and traditional therapies for Demodex blepharitis
- Integrate evidence-based therapies into individualized treatment plans for patients with Demodex blepharitis
- Implement structured follow-up protocols and patient education strategies to improve adherence, symptom relief, and quality of life in patients with Demodex blepharitis.
Target Audience
This activity has been designed to meet the educational needs of optometrists and ophthalmologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, and healthcare professionals involved in the management of patients with Demodex blepharitis.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this asynchronous activity for a maximum of 1.0 COPE credit hours.
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Provider(s)/Educational Partner(s)
Evolve Medical Education LLC (Evolve) is a leader in cultivating health care for patients by educating clinical competence of the health care team. Evolve achieves this by developing and distributing high-quality, evidence-based, valid, independent CME/CE activities in a variety of learning formats. These activities are designed to increase clinician’s knowledge, skills, competence and professional performance as well as to promote professional growth, maintenance of licensure, and support quality change in care of patients.
Commercial Support
This activity is supported by an independent educational grant from Tarsus Pharmaceuticals, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 04/15/2026
Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.